GlassScriptPhysician profile
Roan Flenniken
NPI 1023012960
$11,020.01
in general payments reported to CMS, 2019-2025
45 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $1,412 · 2021: $1,845 · 2022: $1,993 · 2023: $1,294 · 2024: $1,259 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,080.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,302.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,225.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $868.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $863.20 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $740.63 | 2019-2025 | |
| Abbvie INC. | $738.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $674.95 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.29 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $593.78 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $443.91 | 2019-2025 | Evenity, Prolia, Otezla |
| Kowa Pharmaceuticals America, INC. | $353.80 | 2019-2024 | Livalo, Seglentis |
| Abbott Laboratories | $240.11 | 2020-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $213.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.39 | 2022-2025 | |
| Amarin Pharma, INC. | $184.05 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roan Flenniken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.